Investigation of the Emerging Nosocomial Wickerhamomyces anomalus Infections at a Chinese Tertiary Teaching Hospital and a Systemic Review: Clinical Manifestations, Risk Factors, Treatment, Outcomes, and Anti-fungal Susceptibility
Open Access
- 6 October 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 12
Abstract
Wickerhamomyces anomalusis an emerging pathogen, which has been associated with clonal outbreaks and poor clinical outcomes. Despite being an important emerging yeasts species, our understanding concerning the microbiological and clinical characteristics of infections due to this species is limited. Herein, we are reporting a retrospective analysis of fungemia patients withW. anomalusfrom a 2,100-bed hospital in Shanghai during 2014–2016. Moreover, we conducted an extensive literature review to gain a deeper clinical and microbiological insights. Detailed clinical data were recorded. Antifungal susceptibility testing (AFST) followed CLSI M27-A3, and isolates were identified using MALDI-TOF MS. In total, 13 patients were identified with a mortality rate of 38.5% (5/13). Central venous catheter (CVC), broad-spectrum antibiotic therapy, total parenteral nutrition (TPN), surgery, and mechanical ventilation were the most frequently observed risk factors. Eight patients (61.5%) experienced mixed bacterial/Candida bloodstream infections, and four patients developed mixed candidemia (MC).W. anomalusisolates showed high minimum inhibitory concentrations (MICs) against all azoles tested and flucytosine, while AMB showed the highestin vitroactivity. Azoles were used for 84.6% (11/13) of the cases, while 36.4% (4/11) of them died. When combining with the AFST data and the literature review, our study highlights the poor efficacy of azoles and optimal efficacy of AMB and LAMB against infections caused byW. anomalus. In conclusion, our study highlights the emerging threat ofW. anomalusaffecting both neonates and adults. Furthermore, our results advocate the use of AMB formulations rather than azoles among patients infected withW. anomalus. Future studies are warranted to reach a definitive consensus regarding the utility of echinocandins among such patients.Keywords
This publication has 46 references indexed in Scilit:
- Risk factors for and clinical implications of mixed Candida/bacterial bloodstream infectionsClinical Microbiology and Infection, 2013
- Progress in Antifungal Susceptibility Testing of Candida spp. by Use of Clinical and Laboratory Standards Institute Broth Microdilution Methods, 2010 to 2012Journal of Clinical Microbiology, 2012
- Pichia anomala Fungal KeratitisCornea, 2008
- Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care settingEuropean Journal of Clinical Microbiology & Infectious Diseases, 2007
- Treatment of Candida glabrata Infection in Immunosuppressed Mice by Using a Combination of Liposomal Amphotericin B with Caspofungin or MicafunginAntimicrobial Agents and Chemotherapy, 2005
- An Outbreak ofPichia anomalaFungemia in a Brazilian Pediatric Intensive Care UnitInfection Control & Hospital Epidemiology, 2005
- A Prospective Observational Study of Candidemia: Epidemiology, Therapy, and Influences on Mortality in Hospitalized Adult and Pediatric PatientsClinical Infectious Diseases, 2003
- Breakthrough Fungemia due to Hansenula anomala in a Leukemic Patient Successfully Treated with Amphotericin BChemotherapy, 1996
- Fungaemia due to Candida pelliculosa in a case of acute pancreatitisMycoses, 1992
- Transient fungaemia due to Candida, pelliculosa in a patient with AIDSMycoses, 1991